Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Up 19.8% in December

Janux Therapeutics, Inc. (NASDAQ:JANX) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 7,680,000 shares, a growth of 19.8% from the December 15th total of 6,410,000 shares. Currently, 16.4% of the company’s stock are sold short. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is currently 7.3 days.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the transaction, the chief executive officer now owns 257,054 shares of the company’s stock, valued at $13,263,986.40. This trade represents a 8.86 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,334 shares of company stock valued at $6,070,020. 29.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

Institutional investors have recently modified their holdings of the company. Amalgamated Bank lifted its position in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares during the period. Plato Investment Management Ltd increased its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the period. Avanza Fonder AB acquired a new position in shares of Janux Therapeutics in the 4th quarter valued at $139,000. Finally, AQR Capital Management LLC acquired a new position in shares of Janux Therapeutics in the 2nd quarter valued at $215,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

NASDAQ:JANX traded up $0.11 during trading hours on Friday, hitting $40.72. The company’s stock had a trading volume of 802,219 shares, compared to its average volume of 815,856. The company has a market capitalization of $2.14 billion, a PE ratio of -34.80 and a beta of 3.23. Janux Therapeutics has a 52-week low of $7.79 and a 52-week high of $71.71. The business’s 50-day moving average is $53.09 and its two-hundred day moving average is $48.34.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The firm’s quarterly revenue was down 82.6% on a year-over-year basis. As a group, analysts predict that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on JANX. UBS Group began coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective on the stock. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Stifel Nicolaus increased their price target on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Finally, BTIG Research lifted their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.